home / stock / frln / frln articles
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) reported initial data from the ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associ...
Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukoc...
News, Short Squeeze, Breakout and More Instantly...
Freeline Therapeutics Holdings plc Company Name:
FRLN Stock Symbol:
NASDAQ Market:
Freeline Therapeutics Holdings plc Website:
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Please find enclosed the presentation of Frontline plc´s fourth quarter 2023 results to be held on the webcast / conference call 29 February, 2024 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...